BUDAPEST, LONDON and PRINCETON, New Jersey, May 22 /PRNewswire/ -- ThalesNano Inc. and sanofi-aventis R&D today announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.
The collaboration will focus on the development and implementation of continuous process technologies from research to full-scale production. The purpose of the project is to study the utilization and application of ThalesNano's integrated continuous process chemistry technologies within the sanofi-aventis drug R&D process from discovery to API production.
"We are delighted to work with sanofi-aventis R&D who have always been at the forefront of applying new methods and technologies to improve the drug discovery and development process," said Dr. Laszlo Urge, CEO of ThalesNano Inc. "The ThalesNano continuous process technology is already well established in the discovery labs of the life sciences industry. Taking it to process scale promises tremendous benefits for our customers in terms of reducing development time, increasing cost efficiency and minimizing environmental impact."
Dr. Christophe Daubie, head of Chemical Development for Paris area at sanofi-aventis R&D said: "this collaboration is important also because it enters into the scope of sanofi-aventis R&D strategy in terms of our constant involvement in safety considerations, quality improvement of our processes with respect to Environmental and Industrial Hygiene aspects, including Green Chemistry."
Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "The
benefits of continuous process chemistry over conventional batch chemistry
includes the rapid synthesis of organic compounds, in particular under
until now unrealizable hazardous reaction conditions. Further benefits
include Green Chemistry by minimizing waste, energy consumption and raw
material use, lab automation, and rapid scale-up from mg to kg quantities,
|SOURCE Thalesnano Nanotechnology Inc|
Copyright©2008 PR Newswire.
All rights reserved